文献速递类风湿关节炎

抗肿瘤坏死因子多价NANOBODY化合物奥佐利珠单抗治疗类风湿关节炎的II/III期试验结果

Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2022-10-03

这项多中心、双盲、平行组、安慰剂对照II/III期试验纳入381例甲氨蝶呤(MTX)治疗后疾病仍活动的类风湿关节炎(RA)患者,随机接受安慰剂、奥佐利珠单抗30 mg或80 mg联合MTX皮下注射每4周一次共24周。第16周ACR20应答率在奥佐利珠单抗30 mg组为79.6%、80 mg组为75.3%,均显著高于安慰剂组的37.3%(P<0.001)。

要点

  • 第16周ACR20应答率:奥佐利珠单抗30 mg组79.6%、80 mg组75.3%,安慰剂组37.3%(P<0.001)。
  • 两个奥佐利珠单抗组的结构无进展(ΔSHS≤0)比例均显著高于安慰剂组。
  • 严重不良事件:30 mg组4例,80 mg组5例;与其它抗TNF抗体相比未见新的安全性信号。

核心结论

  • 在活动性RA患者中,奥佐利珠单抗联合MTX较安慰剂显著减轻RA的体征和症状。
  • 奥佐利珠单抗耐受性可接受,与其他抗肿瘤坏死因子抗体相比未见新的安全性信号。

研究设计与样本

  • 多中心、双盲、平行组、安慰剂对照II/III期试验,381例患者随机接受安慰剂、奥佐利珠单抗30 mg或80 mg联合MTX皮下注射,每4周一次,共24周。
  • 主要终点为第16周基于美国风湿病学会20%改善标准(ACR20)的应答率和基线至第24周Sharp/van der Heijde评分变化(ΔSHS)。

主要发现

  • 第16周ACR20应答率:奥佐利珠单抗30 mg组79.6%、80 mg组75.3%,均显著高于安慰剂组37.3%(P<0.001),且从治疗第1周即观察到改善。
  • 结构无进展(ΔSHS≤0)患者比例在两个奥佐利珠单抗组均显著高于安慰剂组。
  • 部分次要终点从第3天起即观察到显著更大的改善。
  • 严重不良事件发生于奥佐利珠单抗30 mg组4例患者和80 mg组5例患者。

关键数值与推荐

  • 第16周ACR20应答率:奥佐利珠单抗30 mg组79.6% vs 安慰剂组37.3%(P<0.001)。
  • 第16周ACR20应答率:奥佐利珠单抗80 mg组75.3% vs 安慰剂组37.3%(P<0.001)。
  • 结构无进展(ΔSHS≤0)患者比例在两个奥佐利珠单抗组均显著高于安慰剂组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of subcutaneous administration of 30 mg or 80 mg of ozoralizumab plus methotrexate (MTX) in patients with rheumatoid arthritis (RA) whose disease remained active despite MTX therapy. METHODS: In this multicenter, double-blind, parallel-group, placebo-controlled phase II/III trial, 381 patients were randomized to receive placebo, ozoralizumab 30 mg, or ozoralizumab 80 mg, plus MTX subcutaneously injected every 4 weeks for 24 weeks. The primary end points were the response rates based on the American College of Rheumatology 20% improvement criteria (ACR20) at week 16 and change in the Sharp/van der Heijde score (ΔSHS) from baseline to week 24. RESULTS: The proportion of patients with an ACR20 response at week 16 was significantly higher (P < 0.001) in both ozoralizumab groups (79.6% for 30 mg, 75.3% for 80 mg), compared with placebo (37.3%); these improvements were observed from the first week of treatment. The proportion of the patients with structural nonprogression (ΔSHS ≤0) was significantly higher in both ozoralizumab groups than in the placebo group. For some secondary end points, significantly greater improvements were observed starting from as early as day 3. Serious adverse events occurred in 4 patients in the ozoralizumab 30-mg group and 5 patients in the ozoralizumab 80-mg group. CONCLUSION: In patients with active RA who received ozoralizumab in combination with MTX, the signs and symptoms of RA were significantly reduced as compared with the outcomes in those receiving placebo. Ozoralizumab demonstrated acceptable tolerability with no new safety signals when compared with other antibodies against tumor necrosis factor.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Takeuchi T, Kawanishi M, Nakanishi M, et al. Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2022. PMID: 35729713. doi:10.1002/art.42273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。